Amount of increase (decrease) in the value of a contingent consideration liability, including, but not limited to, differences arising upon settlement.

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=109223946&loc=d3e3602-108585

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 30
-Section 50
-Paragraph 4
-Subparagraph (a)(1)
-URI http://asc.fasb.org/extlink&oid=35744584&loc=d3e7008-128479

+ Details

Name:	us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

No definition available.

+ Details

Name:	us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Definition

Amount of gain (loss) from deconsolidation of subsidiary and derecognition of group of assets constituting transfer of business or nonprofit activity, excluding conveyance of oil and gas mineral rights and transfer of good or service in contract with customer.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 50
-Paragraph 1B
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=109239629&loc=SL4582445-111684

+ Details

Name:	us-gaap_DeconsolidationGainOrLossAmount
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Amount of impairment loss resulting from write-down of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit to fair value.

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 30
-Section 50
-Paragraph 3
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=66006027&loc=d3e16373-109275

Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=109223946&loc=d3e3602-108585

+ Details

Name:	us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-Subparagraph (h)
-URI http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(h))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 20
-Section 45
-Paragraph 2
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=109238882&loc=d3e38679-109324

+ Details

Name:	us-gaap_IncomeTaxExpenseBenefit
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

The amount of the up-front license fee paid by the entity pursuant to a collaborative arrangement.

+ References

No definition available.

+ Details

Name:	vrtx_CollaborativeArrangementUpFrontLicenseFee
Namespace Prefix:	vrtx_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

The aggregate revenue from collaborative revenues. It includes the revenues earned by the entity from nonrefundable, up-front license fees; net reimbursements of research and/or development efforts, including manufacturing services; and milestone payments.

+ References

No definition available.

+ Details

Name:	vrtx_CollaborativeRevenues
Namespace Prefix:	vrtx_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Income Tax Expense (Benefit), Attributable To Decrease In The Fair Value Of Contingent Consideration Liability

+ References

No definition available.

+ Details

Name:	vrtx_IncomeTaxExpenseBenefitAttributableToDecreaseInTheFairValueOfContingentConsiderationLiability
Namespace Prefix:	vrtx_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Income Tax Expense (Benefit), Attributable To Intangible Asset Impairment

+ References

No definition available.

+ Details

Name:	vrtx_IncomeTaxExpenseBenefitAttributableToIntangibleAssetImpairment
Namespace Prefix:	vrtx_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Details

Name:	vrtx_CollaborativeArrangementsByAgreementAxis=vrtx_ParionSciencesInc.Member
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_VariableInterestEntitiesByClassificationOfEntityAxis=us-gaap_VariableInterestEntityPrimaryBeneficiaryMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

Collaborative Arrangements - Parion Sciences, Inc. (Details) - USD ($) $ in Thousands	3 Months Ended								12 Months Ended
	Dec. 31, 2018	Sep. 30, 2018	Jun. 30, 2018	Mar. 31, 2018	Dec. 31, 2017	Sep. 30, 2017	Jun. 30, 2017	Mar. 31, 2017	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
(Benefit from) provision for income taxes	$ (1,492,599)	$ 8,055	$ 10,341	$ (12,659)	$ 10,257	$ (125,903)	$ 4,337	$ 3,985	$ (1,486,862)	$ (107,324)	$ 16,665
Intangible asset impairment charges	$ 29,000	$ 0	$ 0	$ 0	$ 0	255,340	0	$ 0	29,000	255,340	0
Parion Sciences, Inc
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Up-front payment									85,000			$ 85,000
Collaborative and royalty revenues						20,000	$ 20,000
(Benefit from) provision for income taxes						(126,200)
Intangible asset impairment charges						255,300
Business combination, contingent consideration arrangements, change in amount of contingent consideration, liability						(69,600)
Income tax expense (benefit), attributable to intangible asset impairment						(97,700)
Income tax expense (benefit), attributable to decrease in the fair value of contingent consideration liability						$ (28,500)
Deconsolidation, gain (loss), amount									(7,100)	(7,100)
Variable Interest Entity, Primary Beneficiary
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
(Benefit from) provision for income taxes									(3,668)	(114,090)	16,743
Business combination, contingent consideration arrangements, change in amount of contingent consideration, liability									17,730	(62,560)	54,850
Variable Interest Entity, Primary Beneficiary \| Parion Sciences, Inc
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Collaborative and royalty revenues										40,000
(Benefit from) provision for income taxes										14,800
Business combination, contingent consideration arrangements, change in amount of contingent consideration, liability									$ 0	$ (63,460)	$ 64,800